UnitedHealthcare ERT Gaucher Coverage Update

Coverage Criteria for ERT in Gaucher Disease

inv-01: VPRIV (velaglucerase alfa) — Type 1 initial and continuation therapy

VPRIV is proven and medically necessary for treatment of Type 1 Gaucher disease when ALL of the following are met:

VPRIV Type 1 initial therapy: Diagnosis of Type 1 Gaucher disease; symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); dosing is in accordance with FDA‑approved labeling; initial authorization will be for no more than 12 months.

See continuation node for renewal criteria

VPRIV Type 1 continuation: Documentation of positive clinical response to therapy (e.g., reduced severity or resolution of anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); dosing is in accordance with FDA‑approved labeling; continuation authorization will be for no more than 12 months.

inv-02: VPRIV (velaglucerase alfa) — Type 1 continuation therapy

Continuation of VPRIV for Type 1 is medically necessary when ALL of the following are met:

inv-03: Elelyso (taliglucerase alfa) — Type 1 initial and continuation therapy

Elelyso is medically necessary for Type 1 Gaucher disease when ALL of the following are met:

Elelyso Type 1 initial: Diagnosis of Type 1 Gaucher disease; symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); and ONE of the following: history of failure of VPRIV due to failure to meet clinical goals despite VPRIV therapy OR history of failure of VPRIV due to hypersensitivity to VPRIV therapy; dosing is in accordance with FDA‑approved labeling; initial authorization will be for no more than 12 months.

Elelyso Type 1 continuation: Documentation of positive clinical response to therapy; dosing is in accordance with FDA‑approved labeling; continuation authorization will be for no more than 12 months.

inv-04: Cerezyme (imiglucerase) — Type 1 initial and continuation therapy

Cerezyme is medically necessary for Type 1 Gaucher disease when ALL of the following are met:

Cerezyme Type 1 initial: Diagnosis of Type 1 Gaucher disease; symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); and ONE of the following: history of failure of VPRIV due to failure to meet clinical goals despite VPRIV therapy OR history of failure of VPRIV due to hypersensitivity to VPRIV therapy; dosing is in accordance with FDA‑approved labeling; initial authorization will be for no more than 12 months.

Cerezyme Type 1 continuation: Documentation of positive clinical response to therapy; dosing is in accordance with FDA‑approved labeling; continuation authorization will be for no more than 12 months.

inv-05: VPRIV and Cerezyme — Type 3 therapy

Enzyme replacement therapy for Type 3 Gaucher disease is medically necessary when ALL of the following are met:

Type 3 initial: Diagnosis of Type 3 Gaucher disease; symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); dose does not exceed 60 units/kg every 2 weeks; initial authorization will be for no more than 12 months.

Applies to VPRIV (explicit) and Cerezyme (when history of VPRIV failure or hypersensitivity).

Type 3 continuation: Documentation of positive clinical response to therapy (e.g., reduced severity or resolution of anemia, thrombocytopenia, bone disease, hepatomegaly, splenomegaly); dose does not exceed 60 units/kg every 2 weeks; continuation authorization will be for no more than 12 months.

inv-06: Supporting clinical evidence and guideline context

Supporting evidence and guidance relevant to coverage decisions (no discrete eligibility algorithm present in this excerpt):

Velaglucerase alfa switch evidence: Studies report that patients (including children ≥2 years) stable on imiglucerase can be switched to velaglucerase alfa at equivalent dosing with maintained hemoglobin, platelet counts and organ volumes over 12 months and acceptable tolerability.

Multicenter open‑label study n=40; home infusions common; some reversible liver volume increases noted in a small subset.

Pregnancy and ERT: Post‑marketing observational data and cohort analyses indicate velaglucerase alfa and ERT in general are associated with favorable pregnancy outcomes (live birth rate 84% in one series) and that ERT during pregnancy reduces risk of early postpartum hemorrhage and RBC transfusions compared with pregnancies without ERT.

Registry/clinic series and cohort analyses; sample sizes limited.

Comparative efficacy: A Cochrane review and randomized trials suggest recombinant glucocerebrosidases are bio‑similar/non‑inferior on surrogate biological response parameters during the first year; ERT at 30–45 units/kg every 2–4 weeks was generally as effective as 60 units/kg for assessed outcomes.

This Medical Benefit Drug Policy does not apply in certain states that reference state-specific policies or guidelines. Refer to the state-specific policy where noted for Indiana, Kansas, Louisiana, Ohio, Pennsylvania, and Texas. For Florida, this policy only applies to J3060 (Elelyso® / taliglucerase); other enzyme replacement products for Florida should be reviewed under the state's Medicaid clinical policy. Verify the applicable federal, state, or contractual benefit plan terms before applying this policy.

Professional society guidance consistently indicates that enzyme replacement therapy (ERT) is not effective for central nervous system involvement in Type 2 or Type 3 Gaucher disease. Treatment decisions for patients at risk of neuronopathic disease should be based on non-neurological manifestations (visceral and hematologic), and ERT should not be initiated solely to prevent neurologic progression.

When considering initial therapy for Type 1 Gaucher disease, the policy requires that dosing be in accordance with FDA-approved labeling and that documentation of symptomatic disease be provided. Use of Elelyso (taliglucerase) or Cerezyme (imiglucerase) as initial therapy for Type 1 is only supported when there is a documented history of failure of, or hypersensitivity to, VPRIV (velaglucerase alfa); prescribing Elelyso or Cerezyme without documented VPRIV failure or hypersensitivity may not meet the policy's initial therapy criteria.

There is no evidence that enzyme replacement therapy can prevent or slow neurological progression in Type 2 or Type 3 Gaucher disease. Consequently, ERT is not recommended for the neurological manifestations of Type 2 disease and should not be expected to alter neuronopathic disease course.

Applicable Codes and Dosing Limits

Applicable Codesmixed

J1786	Injection, imiglucerase, 10 units
J3060	Injection, taliglucerase alfa, 10 units
J3385	Injection, velaglucerase alfa, 100 units
E75.22	Gaucher Disease

VPRIV dosing limit (Type 3)

VPRIV Type 3 dosing limitDose does not exceed 60 units/kg every 2 weeks

Authorization durationInitial and continuation authorizations limited to no more than 12 months

Indication contextFor treatment of Type 3 Gaucher disease when diagnosis and symptomatic disease documented

Prior Authorization, Documentation, and Utilization Management

Prior Authorization

Prior Authorization Required

Prior authorization is required. Initial authorizations are granted for up to 12 months for ERT (including VPRIV, Elelyso, Cerezyme) when documentation meets the policy's initial criteria (diagnosis, symptomatic disease, and dosing per FDA labeling). Continuation authorizations are granted for up to 12 months when documentation meets continuation criteria, including demonstrated positive clinical response and dosing consistent with FDA labeling.

Initial and continuation authorization durations: up to 12 months
Dosing must be in accordance with FDA-approved labeling
VPRIV is the preferred enzyme replacement therapy

Denial Risk

Triggers for Potential Denial

Coverage may be denied if required documentation is not provided. Examples include absence of documented symptomatic disease, lack of evidence of positive clinical response for continuation requests, dosing that is not consistent with FDA labeling, or missing documentation of prior therapy failure or hypersensitivity when required for Elelyso or Cerezyme.

Definitions and Disease Descriptions

Type 1 Gaucher disease

DefinitionNon‑neuronopathic form of Gaucher disease characterized by systemic manifestations (anemia, thrombocytopenia, hepatomegaly, splenomegaly, bone disease) and accounts for >90% of cases.

Typical treatmentIndicated for long‑term enzyme replacement therapy (imiglucerase, velaglucerase alfa, taliglucerase alfa).

Clinical featuresPresents with visceral and hematologic manifestations without primary central nervous system involvement.

Type 3 Gaucher disease

DefinitionChronic neuronopathic Gaucher disease with subacute neurologic symptoms plus systemic manifestations (e.g., anemia, thrombocytopenia, hepatomegaly, splenomegaly, bone disease).

ERT role

Background on Gaucher Disease and ERT

Gaucher disease is an inherited autosomal recessive disorder caused by deficiency of the lysosomal enzyme glucocerebrosidase, leading to accumulation of glucocerebroside in the liver, spleen, bone marrow and other tissues. The disease produces systemic manifestations including anemia, thrombocytopenia, hepatomegaly, splenomegaly, and bone disease. Type 1 is the non-neuronopathic and most common form (>90% of cases), Type 2 is acute neuronopathic with early life mortality, and Type 3 is chronic neuronopathic with both neurologic and systemic features. Intravenous recombinant glucocerebrosidase agents (for example, imiglucerase, velaglucerase alfa, taliglucerase alfa) are used as enzyme replacement therapy to replace deficient enzyme activity and treat the visceral and hematologic manifestations of Gaucher disease.

OpenPayer

Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease

Coverage Criteria for ERT in Gaucher Disease

Applicable Codes and Dosing Limits

Prior Authorization, Documentation, and Utilization Management

Definitions and Disease Descriptions

Background on Gaucher Disease and ERT